Serum osteoprotegerin levels and long-term prognosis in patients with stable angina pectoris

Atherosclerosis

Volumn 212, Issue 2, 2010, Pages 644-649

  Pedersen, Eva Ringdal ^a   Ueland, Thor ^b   Seifert, Reinhard ^c   Aukrust, Pål ^b,d   Schartum Hansen, Hall ^a   Ebbing, Marta ^c   Bleie, Øyvind ^c   Igland, Jannicke ^a   Svingen, Gard ^c   Nordrehaug, Jan Erik ^a,c   Nygård, Ottar ^a,c  

^a UNIVERSITY OF BERGEN   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Acute myocardial infarction; Mortality; Osteoprotegerin; Stable angina pectoris

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPROTEGERIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; STABLE ANGINA PECTORIS;

AGED; ANGINA PECTORIS; ANGIOGRAPHY; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OSTEOPROTEGERIN; PROGNOSIS; RISK FACTORS;

EID: 77957720102     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.06.027     Document Type: Article

References (30)

1. Kiel D.P., Kauppila L.I., Cupples L.A., et al. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif Tissue Int 2001, 68:271-276.
2. Schulz E., Arfai K., Liu X., et al. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004, 89:4246-4253.
3. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004, 95:1046-1057.
4. Walsh M.C., Choi Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev 2003, 14:251-263.
5. Sandberg W.J., Yndestad A., Oie E., et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006, 26:857-863.
6. Van Campenhout A., Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009, 204:321-329.
7. Venuraju S.M., Yerramasu A., Corder R., Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010, 55:2049-2061.
8. Jono S., Ikari Y., Shioi A., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002, 106:1192-1194.
9. Ziegler S., Kudlacek S., Luger A., Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005, 182:175-180.
10. Kiechl S., Schett G., Wenning G., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109:2175-2180.
11. Emanuele E., Peros E., Scioli G.A., et al. Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer's disease. Int J Mol Med 2004, 13:849-853.
12. Golledge J., McCann M., Mangan S., et al. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004, 35:1636-1641.
13. Semb A.G., Ueland T., Aukrust P., et al. Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol 2009, 29:975-980.
14. Ueland T., Jemtland R., Godang K., et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004, 44:1970-1976.
15. Omland T., Ueland T., Jansson A.M., et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008, 51:627-633.
16. Jensen J.K., Ueland T., Atar D., et al. Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. J Intern Med 2009, 267:410-417.
17. Minoretti P., Falcone C., Calcagnino M., et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006, 27:802-807.
18. Zhu S., Melcer T., Sun J., et al. Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med 2000, 18:305-311.
19. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-13.
20. Ueland T., Bollerslev J., Godang K., et al. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess - possible role in bone homeostasis. Eur J Endocrinol 2001, 145:685-690.
21. Hastie T., Sleeper L., Tibshirani R. Flexible covariate effects in the proportional hazards model. Breast Cancer Res Treat 1992, 22:241-250.
22. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. [discussion 207-12].
23. R Development Core Team. R: A Language and Environment for Statistical Computing; 2008. ISBN 3-900051-07-0, URL http://www.r-project.org/.
24. Nybo M., Johnsen S.P., Dethlefsen C., et al. Lack of observed association between high plasma osteoprotegerin concentrations and ischemic stroke risk in a healthy population. Clin Chem 2008, 54:1969-1974.
25. Ueland T., Yndestad A., Oie E., et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005, 111:2461-2468.
26. Mosheimer B.A., Kaneider N.C., Feistritzer C., et al. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab 2005, 90:2964-2971.
27. Clarke R., Shipley M., Lewington S., et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999, 150:41-353.
28. Sennels H.P., Jacobsen S., Jensen T., et al. Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein. Scand J Clin Lab Invest 2007, 67:821-835.
29. Joseph F., Chan B.Y., Durham B.H., et al. The circadian rhythm of osteoprotegerin and its association with parathyroid hormone secretion. J Clin Endocrinol Metab 2007, 92:3230-3238.
30. McClung M.R., Lewiecki E.M., Cohen S.B., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354:821-831.